For the Inventor, By the Inventor

Enter assignee name

Philogen S.p.a.

USPTO Granted Patents = 50

% Expired Patents = 44.0

CIPO Patents = 11

EPO Patents = 33

Trademarks = 4

Forward Citations = 142

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Dario Neri (22 out of 41 patents)

Kathrin Schwager (9 out of 9 patents)

Giovanni Neri (8 out of 9 patents)

4. Sarah Wulhfard (8 out of 8 patents)

5. Alessandra Villa (7 out of 7 patents)

6. Luciano Zardi (7 out of 7 patents)

7. Barbara Carnemolla (6 out of 6 patents)

8. Manuela Kaspar (5 out of 6 patents)

9. Eveline Trachsel (5 out of 5 patents)

10. Roberto De Luca (4 out of 4 patents)

11. Francesca Pretto (4 out of 4 patents)

12. Jascha-Nikolai Rybak (4 out of 4 patents)

13. Christoph Rosli (4 out of 4 patents)

14. Laura Gualandi (3 out of 3 patents)

15. Gregory Paul Winter (3 out of 75 patents)

Core Competencies:

TNF-alpha

IL-12

Antibody Compositions

Fibronectin

Immunoconjugates

Tumor Antigens

Neovasculature

Angiogenesis

Inflammatory Bowel Disease

Rheumatoid Arthritis

Immunocytokines

Combination Therapy

50 patents: Sort by Forward Citations

1. 12377161 - TNF-alpha immunoconjugate therapy for the treatment of brain tumors (2025-08-05),

2. 12173044 - EDB targeting IL-12 compositions (2024-12-24),

3. 12023381 - Antibody compositions (2024-07-02),

4. 11872288 - TNF-alpha immunoconjugate therapy for the treatment of brain tumors (2024-01-16),

5. 11629199 - Antibodies to tumour antigens (2023-04-18),

6. 11390666 - Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins (2022-07-19),

7. 11351257 - Antibody compositions (2022-06-07),

8. 11274133 - IL2 and TNF immunoconjugates (2022-03-15),

9. 11103592 - IL2 and TNF mutant immunoconjugates (2021-08-31),

10. 10906963 - Non-glycosylated anti-tenascin antibody (2021-02-02),

11. 10858411 - IL22 immunoconjugates (2020-12-08),

12. 10647760 - Antibodies for treatment and diagnosis of inflammatory bowel disease (2020-05-12),

13. 10519246 - Anti-fibroblast activation protein (FAP) antibodies for treatment and diagnosis (2019-12-31),

14. 10385121 - Antigen associated with rheumatoid arthritis (2019-08-20),

15. 10344079 - Methods of treating a neoplastic disease (2019-07-09),

Philogen S.p.a., based in Siena, Italy, specializes in the development of innovative immunotherapy antibodies aimed at treating various cancers and inflammatory diseases. The company focuses on advanced therapeutic modalities, leveraging its expertise in TNF-alpha, IL-12, and antibody compositions to create targeted treatments. Philogen's research encompasses critical areas such as immunoconjugates, tumor antigens, and neovasculature, contributing to the understanding and manipulation of angiogenesis for therapeutic benefit.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Philogen S.p.a.

50 Patents

#1 in

#183 in

#13,981 in the World

Philogen S.p.a.

Forward Citations = 142

62 inventors:

Dario Neri (22 out of 41 patents)

Kathrin Schwager (9 out of 9 patents)

Giovanni Neri (8 out of 9 patents)

4. Sarah Wulhfard (8 out of 8 patents)

5. Alessandra Villa (7 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…